AdverseEvent.ai

Shower To Shower Powder

FDA adverse event reports for this product.

16,832
Total reports
Ovarian Cancer
Top reaction

Top reactions reported

MedDRA Preferred Terms, ranked by frequency in the reports. Shown as percent of all reports for this product. A single report can list multiple reactions, so percentages can sum above 100%.

Ovarian Cancer
31%
Ovarian Cancer Stage Iii
16%
Ovarian Cancer Stage I
16%
Injury
9%
Ovarian Cancer Stage Iv
8%
Ovarian Cancer Stage Ii
6%
Fallopian Tube Cancer
4%
Malignant Peritoneal Neoplasm
4%
Endometrial Cancer Stage I
3%
Fallopian Tube Cancer Stage Iii
3%
Endometrial Cancer
2%
Uterine Cancer
2%
Cervix Carcinoma
1%
Neoplasm Malignant
<1%
Fallopian Tube Cancer Stage I
<1%

Outcomes

How the reports resolved, shown as percent of all reports. Outcomes can overlap (one report can have multiple outcomes), so percentages do not sum to 100%.

Other Serious or Important Medical Event
91%
Death
34%
Hospitalization
30%
Congenital Anomaly
<1%
Required Intervention
<1%
Disability
<1%
Life Threatening
<1%

What to do next

Tools for reporting or tracking adverse events — both for cosmetics and the wider universe of prescription and OTC drugs.

Share this page

About this data

This page summarizes adverse event reports from the FDA's adverse event reporting system for cosmetic products. Reactions are coded in MedDRA. Reports come from consumers, health professionals, and industry. The presence of a report does not establish that the product caused the event - it only reflects what was reported to FDA.

Limitations: The public dataset does not include free-text case narratives, only structured fields.

Data as of June 16, 2026. Source: FDA.